Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$1.67 - $2.55 $2.43 Million - $3.71 Million
1,456,311 New
1,456,311 $3 Million
Q4 2022

Feb 14, 2023

BUY
$3.89 - $8.57 $1.47 Million - $3.23 Million
376,716 New
376,716 $1.62 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $310M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Cvi Holdings, LLC Portfolio

Follow Cvi Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cvi Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cvi Holdings, LLC with notifications on news.